Orchard Therapeutics, a clinical-stage biotechnology company, is opening a second facility for technical operations in the San Francisco Bay Area.

In combination with their existing site, they say the new facility quadruples Orchard’s laboratory footprint for the technical operations that support development, validation of processes, and controls for the manufacture of their gene therapy products.

Orchard’s pipeline includes clinical and pre-clinical stage autologous and ex-vivo lentiviral gene therapies for primary immune deficiencies and inherited metabolic disorders. Their lead product, OTL-101, is in late-stage development and is anticipated to progress to a Biological License Application with the FDA in 2018. The OTL-101 development program has received a $19 million award from the California Institute for Regenerative Medicine.

“The new facility in Menlo Park reflects the rapid growth of our pipeline of transformative gene therapies. In concert with our facility expansion, we look forward to continuing to attract first class technical and management talent to the many career opportunities we are creating in our California operation.” said Mark Rothera, president and chief executive officer of Orchard.